SCHEMBL10272059

SCHEMBL10272059

CCc1nnc(-c2ccco2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.58
ALDH1A1 P00352 10/20 0.57
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
HPGD P15428 2/20 0.52
HTT P42858 1/20 0.48
HSD17B10 Q99714 4/20 0.46
USP2 O75604 1/20 0.46
PPARG P37231 1/20 0.46
NCOA2 Q15596 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
POLB P06746 4/20 0.44
TP53 P04637 2/20 0.44
GLA P06280 2/20 0.44
MAPT P10636 1/20 0.44
PABPC1 P11940 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10054150 0.77 KDM4E (0.64) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL23212489 0.74 ALDH1A1 (0.65) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL970071 0.73 ALDH1A1 (0.62) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL570555 0.73 ALDH1A1 (1.00) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL8536020 0.72 KDM4E (0.58) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL10220036 0.72 KDM4E (0.58) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL17777362 0.72 KDM4E (0.46) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6693068 0.71 SIRT1 (0.58) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL8402852 0.71 ALDH1A1 (0.52) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL22619882 0.70 KDM4E (0.53) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131064-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2013-05-23 US disclosed
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 US disclosed
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 US disclosed
US-7863291-B2 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2011-01-04 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 KDM4E 3667/4885ALDH1A1 1082/4885NPC1 896/4885
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 KDM4E 3667/4885ALDH1A1 1082/4885NPC1 896/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 KDM4E 3667/4885ALDH1A1 1082/4885NPC1 896/4885
US-20130131064-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 KDM4E 3667/4885ALDH1A1 1082/4885NPC1 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.